Procarta’s novel pipeline and DNA-based compounds have the potential to revolutionise the treatment of serious and life-threatening infection, including those caused by multiple drug resistant pathogens.

In order to build and progress Procarta’s pipeline we are pursuing a collaborative approach. As such, we welcome strategic partnering opportunities in our antimicrobial programmes with a focus on;

  • Enterobacteriaceae / CRE
  • Streptococcus / Staphylococcus / MRSA
  • Clostridium difficile
  • Respiratory pathogens
  • Platform capability for specific bacterial species or populations

In order to expand R&D capabilities and our pipeline, we also welcome partnership in Microbiota engineering to provide opportunities to advance the field of precision medicine.